Eine Prospektive, Offene, Multizentrische, Nicht-interventionelle Studie Zur Erhebung Von Daten Zur Anwendung Von Grass MATA MPL 27 600 SU Und Compliance in Der täglichen Klinischen Praxis Bei Erwachsenen Gräserpollen- Allergikern
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
⁃ At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who
• are male and female patients
• are 18 years of age or older
• treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.
• Patients will only be enrolled in the study after the treatment decision has been made
Locations
Other Locations
Germany
Dr. Kasche
RECRUITING
Hamburg
Contact Information
Primary
Ralph Mösges, Univ. Prof. Dr. med. Dipl.-Ing
Ralph.Moesges@Uni-Koeln.de
+49 172 2056 230
Time Frame
Start Date: 2026-03-11
Estimated Completion Date: 2028-10-02
Participants
Target number of participants: 1000
Treatments
Grass Allergic adults
Adult patients aged ≥ 18 for whom pre-seasonal subcutaneous allergen immunotherapy (AIT) with Grassmuno ® is indicated for the treatment of IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis with no asthma or with well-controlled asthma elicited by grass pollen allergy
Related Therapeutic Areas
Sponsors
Collaborators: ClinCompetence Cologne GmbH, Bencard Allergie GmbH
Leads: Allergy Therapeutics